MPSYF News and Press, Morphosys Ag Ord From 01/08/24

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, Ca...

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showe...

2023-11-19 18:59:11 ET Summary MorphoSys reported Q3 2023 earnings with underperformance in Monjuvi sales due to competition and market saturation. There is optimism surrounding the upcoming data readout for Pelabresib, a promising myelofibrosis treatment. The company has a he...

2023-11-16 17:45:02 ET MorphoSys AG (MOR) Q3 2023 Earnings Conference Call November 16, 2023 08:00 AM ET Company Participants Julia Neugebauer - Head of IR Jean-Paul Kress - CEO Tim Demuth - Chief Research and Development Officer Lucinda Crabtree - CFO ...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST). MorphoSys' Management team wil...

2023-11-08 15:07:59 ET More on Xencor Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $...

2023-11-02 10:07:57 ET More on I-Mab, Morphic, etc. Morphic Holding: The Price Drop Is Very Interesting I-Mab: Why This Company Trades At A Third The Value Of Its Cash I-Mab (IMAB) Q2 2023 Earnings Call Transcript MorphoSys expects a 5% surge in Monjuvi sales...

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH ...

2023-10-25 05:54:08 ET More on MorphoSys MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run MorphoSys: Stable Liquidity Amid Challenging Markets Seeking Alpha’s Quant Rating on MorphoSys Historical earnings data for MorphoSys For furt...

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin ...